Evercore ISI believes Regeneron’s (REGN) acquisition of 23andMe for $256M announcement should remove the downside scenario where OraSure’s (OSUR) 23andMe contribution will be zero into perpetuity. Instead, the firm expects 23andMe should continue to be a “meaningful customer going forward” for OraSure. The company has previously disclosed that Regeneron is already an existing customer, which should bode well for a continued relationship between OraSure and 23andMe, the analyst tells investors in a research note. Evercore estimates that 23andMe was a $13M customer for OraSure in 2024. It keeps an In Line rating on the shares with a $3 price target.
Confident Investing Starts Here:
-
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
-
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. >;elm:context_link;itc:0;sec:content-canvas" href="https://thefly.com/?utm_source=finance.yahoo.com&utm_medium=referral" rel="nofollow noopener" target="_blank">Try Now>>
Read More on OSUR:
Latest News
- Novo Nordisk Woes Just Hit Denmark’s Economy. The Stock Is Rising.
- Craig Moffett Believes the Charter-Cox Merger is “Mostly About Wireless”
- The No. 1 Way Americans Become Millionaires Is Pretty Boring — and Easy To Do
- Bernstein Maintains Buy Rating on Nvidia as ‘Jensanity’ Hits Taiwan
- Stock Market Today: Dow Jones Falls, S&P 500 Ends Win Streak; Coffee Kiosks Stock Sinks
- Deutsche Bank Analyst Thinks UnitedHealth Group’s “Issues Are Manageable”
